Simtra Opens $250 Million Building H in Bloomington
The 153,000-square-foot facility adds prefilled syringe, vial, and lyophilization capabilities as demand for sterile drug products grows.
Updated on Nov. 19, 2026 in Business

Simtra BioPharma Solutions opened Building H at its Bloomington, Indiana campus on November 9, 2026, a 153,000-square-foot facility that cost more than $250 million. The ribbon-cutting was attended by Indiana Governor Mike Braun and Bloomington Mayor Kerry Thomson.
Why it matters
Growth in biologics, biosimilars, and GLP-1 therapies is driving demand for sterile drug products, and the expansion adds capacity for that work. Simtra plans to grow from 11 to 18 filling lines across its US and European network by 2027.
Building H cost more than $250 million and covers 153,000 square feet, while Simtra's filling lines are set to grow from 11 to 18 by 2027. Simtra has also invested more than $125 million in its Halle/Westfalen, Germany site, and the projected number of new Bloomington jobs has not been specified.
The players
Simtra BioPharma Solutions
Simtra is a contract development and manufacturing organization focused exclusively on sterile injectables, operating facilities in Bloomington, Indiana and Halle/Westfalen, Germany.
Mike Braun
Mike Braun is the Governor of Indiana, who attended the Building H ribbon-cutting ceremony.
Kerry Thomson
Kerry Thomson is the Mayor of Bloomington, Indiana, who attended the Building H ribbon-cutting ceremony.
The details
Building H adds prefilled syringe, vial, and lyophilization capabilities to Simtra's Bloomington Park Campus, which already received an initial investment of more than $150 million. Simtra is a contract development and manufacturing organization focused exclusively on sterile injectables, and it added a flexible clinical line for prefilled syringes and liquid and lyophilized vials in Bloomington in October 2025.
Timeline
October 2025: Simtra added a flexible clinical line for prefilled syringes and vials in Bloomington.
November 9, 2026: Simtra opened Building H at a ribbon-cutting ceremony.
2027: Simtra targets 18 filling lines across its US and European network.
Market Landscape
Simtra is expanding within the sterile injectables contract manufacturing market, which the stub projects to grow from $41.6 billion in 2026 to $87.3 billion by 2033. The prefilled syringe segment is projected to grow from $9.4 billion in 2026 to $20.3 billion by 2035, positioning Simtra to compete for a larger share of outsourced drug production.
The expansion's projected hundreds of Bloomington jobs could affect local hiring in the healthcare manufacturing sector. Patients receiving prefilled syringes and vial-based injectables may see supply tied to this added capacity, though no pricing changes were reported.
The takeaway
Growth in biologics and GLP-1 therapies is steadily reshaping where injectable medicines are made, and capacity investments like Building H show manufacturers betting on that long-term demand.
Further reading
Explore more on Healthcare industry coverage for context on the sterile injectables sector.
Source note: This article includes information reported by BioPharm International.






